Boehringer Ingelheim
COVID-19
Boehringer Ingelheim is a member of the Corona Accelerated R&D in Europe (CARE), developing therapeutics for COVID-19.1)
The company ran clinical trials for their neutralizing antibody product BI 764198 in COVID-19 patients. The trials were suspended due to lack of efficacy.2)
They also manufacture veterinary ivermectin products and advises against human consumption, instead advocating for COVID-19 vaccination.3)
1)
COVID-19: CARE Consortium. Boehringer Ingelheim. Retrieved January 12, 2022, from https://archive.ph/wiSRG
2)
Study in COVID-19 Patients with Severe Respiratory Illness Discontinued. Boehringer Ingelheim. Retrieved January 12, 2022, from
https://www.boehringer-ingelheim.com/covid-19/fighting-covid-19/research-update
3)
Ivermectin in Animal Health products and COVID-19. Boehringer Ingelheim. Retrieved January 12, 2022, from
https://archive.ph/sSaLf